Beyondspring (BYSI) reversed from ultra low 0.54 to 2.20 now due to very promising trial data…big catalyst – possible Chinese NDA approval of Plinabulum – expected late December early 2023. Has a small free float of 23 mill shares…10,5% short interest…unbelievable short volume of over 11 mill shares during the last three trading days. Daily and weekly chart look very promising…uptrend confirmed on all timeframes…technicals very bullish!. Rise of price fully confirmed with volume.
Also received a very promising, positive e-mail on Dec 15th from head of IR which I have attached.
“
Dear Thomas,
Thank you for your continuous support and interest in BeyondSpring. Similar to many companies in the healthcare industry, BeyondSpring has suffered in this macro-economic crisis, yet the management has been trying very hard to turn stock price around. While we can’t comment on management’s purchase on company’s stock, they are holding the stocks and remain committed to the work BeyondSpring is doing. The team is working diligently with China’s NMPA and looking to provide updates to investors on this soon. Additionally, unlike FDA, China’s NMPA reviews application without a PDUFA date, but our application is being actively reviewed by them now.
Again, thank you for your patience and support. We hope you can remain as our shareholder. The team is working hard to provide news from China soon.
Best regards,
BYSI IR team
“
Leave a Reply